The Use of Botropase in Suprapubic Transvesical Prostatectomy.
- Author:
Kuk Kil KIM
1
;
Jun Ho CHANG
Author Information
1. Department of Urology, East City Hospital, Seoul, Korea.
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
open prostatectomy;
botropase;
BPH
- MeSH:
Bothrops;
Disseminated Intravascular Coagulation;
Hematuria;
Hemorrhage;
Humans;
Inpatients;
Male;
Prostatectomy*;
Venoms
- From:Korean Journal of Urology
1986;27(3):437-441
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
From April, 1980, to April, 1965, 24 male inpatients with suprapubic transvesical prostatectomy due to benign prostatic hypertrophy(B.P.H) were entered in the study. They were randomized into three groups. Intraoperative blood losses were evaluated by weighing the aspirated blood and the blood retained by the gauze tampones. New antihemorrhagic agent, Botropase(Bothrops Jararaca venom extract) was administered intramuscularly or intravenously in 8 cases of suprapubic transvesical prostatectomy due to B.P.H and following result were obtained. 1. Botropase(Bothrops Jararaca venom extract) was found to be useful to lead to reduction of local hemorrhage without any thrombophilic effect on the coagulation and fibrinolytic system. 2. Postoperative hematuria is significantly reduced by the administration of an antifibrinolytic agent. 3. In patients with a high thromboembolic risk, variation of the intra- and postoperativecoagulation and fibrinolytic activities should be carefully assessed; This is in under to prevent with the correct treatment thromboembolic accidents or disseminated intravascular coagulation syndromes. 4. No serious side effects were observed.
